about
MicroRNA-451 regulates LKB1/AMPK signaling and allows adaptation to metabolic stress in glioma cellsIdentification of Raf-1 S471 as a novel phosphorylation site critical for Raf-1 and B-Raf kinase activities and for MEK bindingMicroRNA Signatures and Molecular Subtypes of Glioblastoma: The Role of Extracellular Transfer.MicroRNA 17-92 cluster mediates ETS1 and ETS2-dependent RAS-oncogenic transformationMicroRNA-Mediated Dynamic Bidirectional Shift between the Subclasses of Glioblastoma Stem-like Cells.microRNA-451: A conditional switch controlling glioma cell proliferation and migration.Fusion tyrosine kinases induce drug resistance by stimulation of homology-dependent recombination repair, prolongation of G(2)/M phase, and protection from apoptosis.Glucose-based regulation of miR-451/AMPK signaling depends on the OCT1 transcription factor.Belonging to a network--microRNAs, extracellular vesicles, and the glioblastoma microenvironment.Genetics and genomics of osteoclast differentiation: integrating cell signaling pathways and gene networks.MEK-1 activates C-Raf through a Ras-independent mechanism.SRGAP1 is a candidate gene for papillary thyroid carcinoma susceptibility.Extracellular Vesicles from High-Grade Glioma Exchange Diverse Pro-oncogenic Signals That Maintain Intratumoral HeterogeneitySignificance of 14-3-3 self-dimerization for phosphorylation-dependent target binding.Extracellular vesicles modulate the glioblastoma microenvironment via a tumor suppression signaling network directed by miR-1.Extracellular Vesicles and MicroRNAs: Their Role in Tumorigenicity and Therapy for Brain Tumors.Targeting of the Bmi-1 oncogene/stem cell renewal factor by microRNA-128 inhibits glioma proliferation and self-renewal.The Ewing sarcoma protein (EWS) binds directly to the proximal elements of the macrophage-specific promoter of the CSF-1 receptor (csf1r) gene.PKC and Raf-1 inhibition-related apoptotic signalling in N2a cells.CDK4/6 inhibition is more active against the glioblastoma proneural subtype.A cross-talk network that facilitates tumor virotherapy.Eos, MITF, and PU.1 recruit corepressors to osteoclast-specific genes in committed myeloid progenitors.MicroRNA-128 coordinately targets Polycomb Repressor Complexes in glioma stem cells.Response to energy depletion: miR-451/AMPK loop.Combined CDK4/6 and mTOR Inhibition Is Synergistic against Glioblastoma via Multiple Mechanisms.Targeting the mesenchymal subtype in glioblastoma and other cancers via inhibition of diacylglycerol kinase alpha.CBM-01CHARACTERIZATION OF microRNAome IN GLIOBLASTOMA STEM CELLS AND THEIR EXTRACELLULAR VESICLES.STEM-09MicroRNA-128 IS A MASTER SWITCH BETWEEN PRONEURAL AND MESENCHYMAL SUBTYPE IN GLIOBLASTOMA STEM CELLS.Preclinical investigation of combined gene-mediated cytotoxic immunotherapy and immune checkpoint blockade in glioblastoma.Combined c-Met/Trk inhibition overcomes resistance to CDK4/6 inhibitors in Glioblastoma.Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles.Statins affect human glioblastoma and other cancers through TGF-β inhibition
P50
Q24603505-7F1A1EED-4DD5-43E6-8ABF-C16C108B2609Q28648013-8425D702-C1D1-4440-BA29-4C00848CAB27Q33795249-81766149-68F9-43F1-AC10-F2B29107467EQ33812198-ED330AE8-0891-403F-B5DA-087CAAA6F6FFQ33913752-C8214A66-F030-4576-9029-9108A26CA0A2Q34127211-EE17447B-D251-4997-95F5-3FFFEFF408ACQ34281241-C97A56CD-2E04-4434-93E1-95324A928825Q35607018-E83A048A-8788-4840-ABD5-7F68864CF676Q35788575-855275F1-2854-4CCF-9314-C52816BE37CBQ36638376-E2CD018F-4AC9-431F-B485-1ED6A3C7AFE1Q36717848-3252795E-F583-4C8F-949F-695B97B6AEE3Q36817184-84123941-A312-43D5-8E99-09F3192713ABQ36917711-C60A6AB6-DEE0-4ED2-BD45-AC98B1955C98Q37155705-6C02E9C0-8197-45D2-BBF2-44AA3BCCA444Q37592190-DACADA5E-D662-47E0-AA05-64A5D1AAD52BQ38777383-75EA63F4-FD76-4FDF-8836-4CD4CE139568Q39916475-BAB1118D-15D7-4D0B-B0DA-60FA800BBB97Q39985809-26745CB0-1867-408D-9A9A-512AFFFB1120Q40724519-591C9064-2AE6-4A8A-A8B8-C0C6702FAE8DQ41548769-8C6B8760-3E5B-42DF-A072-85F169203B4EQ41755608-71338E8D-9A64-4F80-B054-3C078A59CA78Q41842422-7D9E83AB-38F5-4222-A622-5383CC8D7016Q41871901-D26D6FF9-3EF6-403D-837F-8E5955FB09CDQ43195541-2466AC85-F892-4F0E-A7EE-EA1E3E60D95EQ45065453-F3C2C0F8-658A-4944-9992-A3F646EA7F36Q45070460-72508707-4350-43C3-82DF-55B37AE75134Q45832121-DC8628FB-DA4E-47CA-AF5F-39A50AA21C86Q45835654-E8AD1976-D6AC-46E9-AEF2-317912AA3140Q47827127-ECED48D1-0BA7-4D0D-9977-5C541D4D8E68Q54977810-D09C94BF-3603-4277-9D07-0CAE618289D2Q55115778-C1DC3055-962C-4736-A775-F3E377096A03Q63976716-2F53CA41-156B-412E-BCFF-7FB354DD8226
P50
description
Polish molecular biologist
@en
Pools onderzoekster
@nl
bitheolaí móilíneach Polannach
@ga
polska biolog molekularna
@pl
հետազոտող
@hy
name
Agnieszka Bronisz
@ast
Agnieszka Bronisz
@ca
Agnieszka Bronisz
@cs
Agnieszka Bronisz
@en
Agnieszka Bronisz
@es
Agnieszka Bronisz
@ga
Agnieszka Bronisz
@gl
Agnieszka Bronisz
@hr
Agnieszka Bronisz
@hsb
Agnieszka Bronisz
@it
type
label
Agnieszka Bronisz
@ast
Agnieszka Bronisz
@ca
Agnieszka Bronisz
@cs
Agnieszka Bronisz
@en
Agnieszka Bronisz
@es
Agnieszka Bronisz
@ga
Agnieszka Bronisz
@gl
Agnieszka Bronisz
@hr
Agnieszka Bronisz
@hsb
Agnieszka Bronisz
@it
prefLabel
Agnieszka Bronisz
@ast
Agnieszka Bronisz
@ca
Agnieszka Bronisz
@cs
Agnieszka Bronisz
@en
Agnieszka Bronisz
@es
Agnieszka Bronisz
@ga
Agnieszka Bronisz
@gl
Agnieszka Bronisz
@hr
Agnieszka Bronisz
@hsb
Agnieszka Bronisz
@it
P214
P1053
G-5980-2019
P1412
P1559
Agnieszka Bronisz
@pl
P21
P214
P27
P31
P3124
P3829
P496
0000-0002-5841-1051
P735
P7859
viaf-315704596